Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma - PubMed (original) (raw)
Clinical Trial
. 2008 Jun 20;26(18):3015-24.
doi: 10.1200/JCO.2007.15.7164.
Eugenia Migliavacca, Thierry Gorlia, Wanyu L Lambiv, Tal Shay, Marie-France Hamou, Nicolas de Tribolet, Luca Regli, Wolfgang Wick, Mathilde C M Kouwenhoven, Johannes A Hainfellner, Frank L Heppner, Pierre-Yves Dietrich, Yitzhak Zimmer, J Gregory Cairncross, Robert-Charles Janzer, Eytan Domany, Mauro Delorenzi, Roger Stupp, Monika E Hegi
Affiliations
- PMID: 18565887
- DOI: 10.1200/JCO.2007.15.7164
Clinical Trial
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
Anastasia Murat et al. J Clin Oncol. 2008.
Abstract
Purpose: Glioblastomas are notorious for resistance to therapy, which has been attributed to DNA-repair proficiency, a multitude of deregulated molecular pathways, and, more recently, to the particular biologic behavior of tumor stem-like cells. Here, we aimed to identify molecular profiles specific for treatment resistance to the current standard of care of concomitant chemoradiotherapy with the alkylating agent temozolomide.
Patients and methods: Gene expression profiles of 80 glioblastomas were interrogated for associations with resistance to therapy. Patients were treated within clinical trials testing the addition of concomitant and adjuvant temozolomide to radiotherapy.
Results: An expression signature dominated by HOX genes, which comprises Prominin-1 (CD133), emerged as a predictor for poor survival in patients treated with concomitant chemoradiotherapy (n = 42; hazard ratio = 2.69; 95% CI, 1.38 to 5.26; P = .004). This association could be validated in an independent data set. Provocatively, the HOX cluster was reminiscent of a "self-renewal" signature (P = .008; Gene Set Enrichment Analysis) recently characterized in a mouse leukemia model. The HOX signature and EGFR expression were independent prognostic factors in multivariate analysis, adjusted for the O-6-methylguanine-DNA methyltransferase (MGMT) methylation status, a known predictive factor for benefit from temozolomide, and age. Better outcome was associated with gene clusters characterizing features of tumor-host interaction including tumor vascularization and cell adhesion, and innate immune response.
Conclusion: This study provides first clinical evidence for the implication of a "glioma stem cell" or "self-renewal" phenotype in treatment resistance of glioblastoma. Biologic mechanisms identified here to be relevant for resistance will guide future targeted therapies and respective marker development for individualized treatment and patient selection.
Similar articles
- Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P, Nanni-Metellus I, Delfino C, Colin C, Tchogandjian A, Coulibaly B, Fina F, Loundou A, Barrie M, Chinot O, Ouafik L, Figarella-Branger D. Metellus P, et al. Ann Surg Oncol. 2011 Oct;18(10):2937-45. doi: 10.1245/s10434-011-1703-6. Epub 2011 Apr 9. Ann Surg Oncol. 2011. PMID: 21479688 Clinical Trial. - Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy.
Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T, Simon M, Westphal M, Schackert G, Tonn JC, von Deimling A, Davis T, Weiss WA, Loeffler M, Reifenberger G; German Glioma Network. Weller M, et al. Int J Cancer. 2014 May 15;134(10):2437-47. doi: 10.1002/ijc.28576. Int J Cancer. 2014. PMID: 24614983 - MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. Donson AM, et al. Pediatr Blood Cancer. 2007 Apr;48(4):403-7. doi: 10.1002/pbc.20803. Pediatr Blood Cancer. 2007. PMID: 16609952 - Mechanisms of disease: temozolomide and glioblastoma--look to the future.
Mrugala MM, Chamberlain MC. Mrugala MM, et al. Nat Clin Pract Oncol. 2008 Aug;5(8):476-86. doi: 10.1038/ncponc1155. Epub 2008 Jun 10. Nat Clin Pract Oncol. 2008. PMID: 18542116 Review. - Predictive biomarkers investigated in glioblastoma.
Tabouret E, Chinot O, Sanson M, Loundou A, Hoang-Xuan K, Delattre JY, Idbaih A. Tabouret E, et al. Expert Rev Mol Diagn. 2014 Sep;14(7):883-93. doi: 10.1586/14737159.2014.945436. Epub 2014 Aug 5. Expert Rev Mol Diagn. 2014. PMID: 25096963 Review.
Cited by
- Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.
Köse SN, Yaraş T, Bursali A, Oktay Y, Yandim C, Karakülah G. Köse SN, et al. Turk J Biol. 2024 Jul 1;48(4):242-256. doi: 10.55730/1300-0152.2700. eCollection 2024. Turk J Biol. 2024. PMID: 39296333 Free PMC article. - hERG channel agonist NS1643 strongly inhibits invasive astrocytoma cell line SMA-560.
Benn KW, Yuan PH, Chong HK, Stylii SS, Luwor RB, French CR. Benn KW, et al. PLoS One. 2024 Sep 6;19(9):e0309438. doi: 10.1371/journal.pone.0309438. eCollection 2024. PLoS One. 2024. PMID: 39240809 Free PMC article. - PL-hMSC and CH-hMSC derived soluble factors inhibit proliferation but improve hGBM cell migration by activating TGF-β and inhibiting Wnt signaling.
Uthanaphun T, Manochantr S, Tantrawatpan C, Tantikanlayaporn D, Kheolamai P. Uthanaphun T, et al. Biosci Rep. 2024 May 29;44(5):BSR20231964. doi: 10.1042/BSR20231964. Biosci Rep. 2024. PMID: 38687607 Free PMC article. - Gene signatures associated with prognosis and chemotherapy resistance in glioblastoma treated with temozolomide.
Carter T, Valenzuela RK, Yerukala Sathipati S, Medina-Flores R. Carter T, et al. Front Genet. 2023 Dec 18;14:1320789. doi: 10.3389/fgene.2023.1320789. eCollection 2023. Front Genet. 2023. PMID: 38259614 Free PMC article. - Drug resistance in glioblastoma: from chemo- to immunotherapy.
Sharma S, Chepurna O, Sun T. Sharma S, et al. Cancer Drug Resist. 2023 Oct 11;6(4):688-708. doi: 10.20517/cdr.2023.82. eCollection 2023. Cancer Drug Resist. 2023. PMID: 38239396 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous